Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6004132 | 0.93 | SLC6A9 (0.64) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6826343 | 0.89 | SLC6A9 (0.73) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6005572 | 0.88 | SLC6A9 (0.74) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6826562 | 0.87 | SLC6A9 (0.80) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6013413 | 0.87 | SLC6A9 (0.80) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6257276 | 0.86 | SLC6A9 (0.69) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6258546 | 0.84 | SLC6A9 (0.66) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6257274 | 0.81 | SLC6A9 (0.51) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL6806417 | 0.81 | SLC6A9 (0.68) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 | |
| SCHEMBL1052569 | 0.80 | SLC6A9 (1.00) | SLC6A9ALDH1A1CYP2D6MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287298-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | ALLELIX NEUROSCIENCE INC. | 2006-12-21 | — | — | US | disclosed |
| EP-1014966-B1 | PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | ALLELIX NEUROSCIENCE INC (US) | 2006-08-02 | — | — | EP | disclosed |
| US-7019024-B2 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | ALLELIX NEUROSCIENCE INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-20010012857-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | NPS PHARMACEUTICALS, INC. | 2001-08-09 | — | — | US | disclosed |
| US-6191165-B1 | ANTIDEPRESSANTS; SCHIZOPHRENIA; ALZHEIMER'S DISEASE; ANTIEPILEPTIC AGENTS | ALLELIX NEUROSCIENCE INC. | 2001-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287298-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | SLC18A2, SLC6A1, SLC6A11 | SLC6A9 58/4885ALDH1A1 806/4885CYP2D6 330/4885 |
| US-20010012857-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | SLC6A1, SLC18A2, SLC6A11 | SLC6A9 75/4885ALDH1A1 357/4885CYP2D6 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.